Gastric
carcinoma (GC) is a severe
tumor of the digestive tract with high morbidity and mortality and poor prognosis, for which novel treatment options are urgently needed. Compound
Kushen injection (CKI), a classical injection of Chinese medicine, has been widely used to treat various
tumors in clinical practice for decades. In recent years, a growing number of studies have confirmed that CKI has a beneficial
therapeutic effect on GC, However, there are few reports on the potential molecular mechanism of action. Here, using systems pharmacology combined with proteomics analysis as a core concept, we identified the
ceRNA network, key targets and signaling pathways regulated by CKI in the treatment of GC. To further explore the role of these key targets in the development of GC, we performed a meta-analysis to compare the expression differences between GC and normal gastric mucosa tissues. Functional enrichment analysis was further used to understand the biological pathways significantly regulated by the key genes. In addition, we determined the significance of the key genes in the prognosis of GC by survival analysis and immune infiltration analysis. Finally, molecular docking simulation was performed to verify the combination of CKI components and key targets. The anti-
gastric cancer effect of CKI and its key targets was verified by in vivo and in vitro experiments. The analysis of
ceRNA network of CKI on GC revealed that the potential molecular mechanism of CKI can regulate PI3K/AKT and
Toll-like receptor signaling pathways by interfering with hub genes such as AKR1B1, MMP2 and PTGERR3. In conclusion, this study not only partially highlighted the molecular mechanism of CKI in GC
therapy but also provided a novel and advanced systems pharmacology strategy to explore the mechanisms of
traditional Chinese medicine formulations.